Now published for US HCPs: results of an IPTW of a BCMA-directed CAR-T cell therapy vs conventional treatment regimens for patients with relapsed/refractory multiple myeloma. Read more: bit.ly/3GCOEQK. #mmsm Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

For US HCPs at #SOHO2025, Yi Lin (Yi Lin) of Mayo Clinic Rochester presents an encore presentation analyzing ALC as a key biomarker for safety monitoring after a BCMA-directed #CART cell therapy. #mmsm

For US #HCPs at #SOHO2025, Surbhi Sidana (Surbhi Sidana, MD) of Stanford University presents an encore presentation analyzing survival outcomes of various subgroups in CARTITUDE-4 of a BCMA-directed #CART therapy versus standard of care. #mmsm

For US HCPs at #WCLC25, see Dr. Adam J. Schoenfeld (Adam J. Schoenfeld) present results from a phase 1 study of a DLL3-targeted #CART cell therapy in small cell lung and large cell neuroendocrine cancers. See more: bit.ly/4g2po3W. #lcsm #sclc #lcnec

For US HCPs at #WCLC25, Dr. Zhonglin Hao (University of Kentucky) presents a case study of a patient with SCLC treated successfully with a DLL3-targeted #CART cell therapy. Read more: bit.ly/4mypO4r. #lcsm #sclc

For US HCPs at #IMS25, Yi Lin (Yi Lin) of Mayo Clinic Rochester presents an encore presentation analyzing ALC as a key biomarker for safety monitoring after a BCMA-directed #CART cell therapy. For IMS abstracts, link here: bit.ly/45VN5Yf. #mmsm

For US HCPs at #IMS25, Surbhi Sidana (Surbhi Sidana, MD) of Stanford University presents a quality-adjusted survival analysis of a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: bit.ly/4pfEirI. #mmsm.

For US HCPs at #IMS25, Dr. Murali Janakiram (Murali Janakiram) from City of Hope presents a descriptive analysis of healthcare resource utilization following inpatient or outpatient infusion of a BCMA-directed #CART therapy. Abstracts here: bit.ly/3IaTAx8. #mmsm

For US HCPs at #IMS25, see Dr. Yael Cohen present updated results from CARTITUDE-2, Cohort D of a BCMA-directed #CART therapy +/- lenalidomide maintenance for multiple myeloma patients with a suboptimal response to frontline ASCT. Abstracts here: bit.ly/3VG16Dg. #mmsm

Thank you to our funders, who make it possible for us to deliver the Multiple Myeloma Hub. Bristol Myers Squibb GSK Pfizer Johnson & Johnson Innovative Medicine Legend Biotech Roche Sanofi #mmsm #MultipleMyeloma